Literature DB >> 2311295

Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

G Zilow1, J A Sturm, U Rother, M Kirschfink.   

Abstract

In vivo and in vitro studies have shown that complement activation plays an important role in the pathogenesis of the adult respiratory distress syndrome (ARDS). In a prospective study of polytrauma patients at risk of ARDS (n = 38) complement parameters were determined over a period of 14 days in serial plasma samples (obtained every 6 h during the first 48 h). Polytrauma induced a rapid and remarkable complement activation. Low levels of the complement proteins C3, C4, C1 inhibitor (C1 INH) factor I and factor H during the first 48 h indicated complement consumption in all patients. Elevated C3a levels in the first few hours after injury were associated with the later development of ARDS. A more sensitive indicator than C3a alone was the calculated C3a:C3 ratio discriminating ARDS and non-ARDS patients. A second rise of C3a levels and C3a:C3 ratio from day 4 on paralleled the course of extravascular lung water. To assess the mode of complement activation, the activation-specific protein complexes C1rC1s-C1 INH and C3b(Bb)P were measured in some of the patients. We demonstrate that in the first 48 h complement activation occurred via the alternative pathway only and was later followed by an additional activation via the classical pathway. Our observations suggest that monitoring of C3a and C3 in plasma can identify polytrauma patients at high risk for ARDS at an early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311295      PMCID: PMC1534766          DOI: 10.1111/j.1365-2249.1990.tb05171.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Complement activation in septic shock patients.

Authors:  C L Sprung; D R Schultz; E Marcial; P V Caralis; M A Gelbard; P I Arnold; W M Long
Journal:  Crit Care Med       Date:  1986-06       Impact factor: 7.598

2.  Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.

Authors:  P F Weinberg; M A Matthay; R O Webster; K V Roskos; I M Goldstein; J F Murray
Journal:  Am Rev Respir Dis       Date:  1984-11

3.  Complement activation in patients at risk of developing the adult respiratory distress syndrome.

Authors:  J Duchateau; M Haas; H Schreyen; L Radoux; I Sprangers; F X Noel; M Braun; M Lamy
Journal:  Am Rev Respir Dis       Date:  1984-12

4.  Adult respiratory distress syndrome: risk with common predispositions.

Authors:  A A Fowler; R F Hamman; J T Good; K N Benson; M Baird; D J Eberle; T L Petty; T M Hyers
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

5.  [Classification of the severity of injury].

Authors:  H J Oestern; H Tscherne; J Sturm; M Nerlich
Journal:  Unfallchirurg       Date:  1985-11       Impact factor: 1.000

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man.

Authors:  J S Solomkin; L A Cotta; P S Satoh; J M Hurst; R D Nelson
Journal:  Surgery       Date:  1985-06       Impact factor: 3.982

8.  Adult respiratory distress syndrome: causes, morbidity, and mortality.

Authors:  T M Hyers; A A Fowler
Journal:  Fed Proc       Date:  1986-01

9.  A study of optimal reaction conditions for an assay of the human alternative complement pathway.

Authors:  K A Joiner; A Hawiger; J A Gelfand
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

10.  Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.

Authors:  J H Stevens; P O'Hanley; J M Shapiro; F G Mihm; P S Satoh; J A Collins; T A Raffin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more
  30 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

3.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

4.  Evaluation of complement activation in premature newborn infants with hyaline membrane disease.

Authors:  R Cat; N A Rosario; I T de Messias; T D Resener; M Kirschfink
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

Review 5.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

6.  Complement activation in neonatal disease.

Authors:  E P Zilow
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

7.  Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.

Authors:  C Cunningham-Rundles; Z Zhou; S Mankarious; S Courter
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

8.  Multiple organ failure (MOF) after severe trauma--a sheep model.

Authors:  H C Pape; M Grotz; D Remmers; A Dwenger; R Vaske; D Wisner; H Tscherne
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

9.  Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons.

Authors:  Ralf Gutzmer; Margarete Lisewski; Jörg Zwirner; Susanne Mommert; Carola Diesel; Miriam Wittmann; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

10.  Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection.

Authors:  Barry Rockx; Tracey Baas; Gregory A Zornetzer; Bart Haagmans; Timothy Sheahan; Matthew Frieman; Matthew D Dyer; Thomas H Teal; Sean Proll; Judith van den Brand; Ralph Baric; Michael G Katze
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.